A phase 3 trial of bevacizumab in ovarian cancer.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  New England Journal of Medicine

• Publication date

  2011-12-28

• Fields of study

  Medicine

• Identifiers
  DOI 10.1056/NEJMoa1103799PMID 22204725
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Incorporation of bevacizumab in the primary treatment of ovarian cancer.

  2011cited by this paper
• Advanced ovarian cancer: phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxel.

  2010cited by this paper
• Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial.

  2009cited by this paper
• Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup.

  2009cited by this paper
• The use of bevacizumab in colorectal, lung, breast, renal and ovarian cancer: where does it fit?

  2008cited by this paper
• Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia.

  2008cited by this paper
• Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study.

  2007cited by this paper
• Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer.

  2007cited by this paper
• Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationau

  2006cited by this paper
• Aspirin for the Primary Prevention of Cardiovascular Events in Women and Men: A Sex-Specific Meta-Analysis of Randomized Controlled Trials

  2006cited by this paper
• Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO.

  2006cited by this paper
• Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer).

  2005cited by this paper
• Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial - E4599

  2005cited by this paper
• Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer).

  2005cited by this paper
• Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

  2004cited by this paper
• Flexible parametric proportional‐hazards and proportional‐odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects

  2002cited by this paper
• Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Gr

  2001cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors

  2000cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

  2000cited by this paper
• Blockade of nuclear factor-kappaB signaling inhibits angiogenesis and tumorigenicity of human ovarian cancer cells by suppressing expression of vascular endothelial growth factor and interleukin 8.

  2000cited by this paper
• Expression of angiogenesis-related genes and progression of human ovarian carcinomas in nude mice.

  1998cited by this paper
• Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer.

  1996cited by this paper
• What is the evidence that tumors are angiogenesis dependent?

  1990cited by this paper
• Anti‐Angiogenesis: New Concept for Therapy of Solid Tumors

  1972cited by this paper
• Appendix

  1838cited by this paper

• Bevacizumab in ovarian cancer: Clinical data and predictive and prognostic biomarkers

  2026cites this paper
• Lymphadenectomy in early-stage ovarian cancer: is there still a role?

  2026cites this paper
• Real-life data on clinical characteristics, treatments and outcomes of patients with newly diagnosed advanced-stage ovarian cancer: an observational study from Belgium.

  2026cites this paper
• Hypoxia-driven remodeling of SELENOP+ macrophages shapes T cell dynamics and promotes ovarian cancer metastasis

  2026cites this paper
• Bevacizumab in Advanced High Grade Serous Ovarian Cancer: The Impact of BRCA Mutation Status

  2026cites this paper
• Immune-Centered Cross-Talk Between Cancer Cells and the Tumor Microenvironment—Implications for Therapy

  2026cites this paper
• Real-World Outcomes of Primary Versus Interval Debulking Surgery in a Multicenter Cohort of Advanced Ovarian Cancer Patients Treated with Bevacizumab

  2026cites this paper
• Impact of vascular endothelial growth factor inhibitor-induced hypertension on continued cancer treatment: a systematic review and meta-analysis.

  2026cites this paper
• Anastomotic leakage after rectosigmoid resection with primary anastomosis during cytoreductive surgery for advanced high-grade serous ovarian cancer: risk factors and oncologic outcomes

  2026cites this paper
• Nachsorge Ovarialkarzinom: zwischen Erhaltungstherapie und Rezidiv

  2026cites this paper
• Metastatic high-grade undifferentiated ovarian carcinoma: A case report from Sub-Saharan Africa

  2026cites this paper
• Comparison of Different Maintenance Treatment Options for Newly Diagnosed BRCAwt Advanced Ovarian Cancer: A Retrospective Cohort Analysis

  2026cites this paper
• Informative censoring in maintenance therapy trials for advanced ovarian cancer: An empirical assessment of its impact on treatment benefit.

  2026cites this paper
• Single-cell transcriptome analysis of patient-derived organoids captures inter- and intratumor heterogeneity and uncovers targetable pathways in high grade serous ovarian cancer.

  2026cites this paper
• Survival analysis of second-line chemotherapy in platinum-sensitive relapsed ovarian cancer patients.

  2026cites this paper
• Double-Blind Randomized Phase 2 Trial Testing Personal Cancer Vaccines in Patients with Advanced Ovarian Cancer

  2025cites this paper
• Impact of Antihypertensive Treatment on Outcomes of Adjuvant Bevacizumab for Ovarian Cancer (IATRO), Results from a Nationwide Emulated Clinical Trial

  2025cites this paper
• Unmet needs and emerging therapeutics in low-grade serous ovarian carcinoma: from chemoresistance to precision medicine

  2025influential citation
• Ex vivo 3D micro-tumour testing platform for predicting clinical response to platinum-based therapy in patients with high-grade serous ovarian cancer

  2025cites this paper
• Surgical and Blood-Based Minimal Residual Disease in Patients with Ovarian Cancer after First-line Therapy: Clinical Outcomes and Translational Opportunities

  2025cites this paper
• Optimizing bevacizumab dosing in first-line ovarian cancer treatment: the PGOG-ov1 trial

  2025cites this paper
• Ketoboronate as a Minimal Covalent-Reversible Tag for Targeted Lysosomal Degradation of Extracellular and Membrane Proteins

  2025cites this paper
• Efficacy of PD-1/PDL-1 inhibitors for ovarian cancer: a systematic review and network meta-analysis.

  2025cites this paper
• Natural Metabolites as Modulators of Sensing and Signaling Mechanisms: Unlocking Anti-Ovarian Cancer Potential

  2025cites this paper
• Unraveling neutrophil diversity in ovarian cancer: bridging clinical insights and basic research

  2025cites this paper
• Mechanisms of drug resistance: PARP inhibitors, antibody-drug-conjugates, and immunotherapy.

  2025cites this paper
• Cancer of the ovary, fallopian tube, and peritoneum: 2025 update

  2025cites this paper
• Phase 3 clinical trials evaluating poly(ADP-ribose) polymerase inhibition plus immunotherapy for first-line treatment of advanced ovarian cancer

  2025cites this paper
• Harnessing ovarian cancer ascites for translational science: models, biomarkers, and therapeutics

  2025cites this paper
• Apoptotic effect of linifanib on human ovarian cancer OVCAR3 cell line

  2025cites this paper
• Efficacy and safety analyses of bevacizumab in neoadjuvant chemotherapy for ovarian cancer: a systematic review and meta-analysis

  2025cites this paper
• Bevacizumab in ovarian cancer therapy: current advances, clinical challenges, and emerging strategies

  2025influential citation
• Sequential Plasma Metabolome and Proteome Analyses to Develop a Novel Monitoring Strategy for Patients with Epithelial Ovarian Cancer: A Pilot Study

  2025cites this paper
• Highlights from the third Colombian conference on women's cancers.

  2025cites this paper
• Identification of a cuproptosis‑related prognostic biomarker and therapeutic target in ovarian cancer

  2025cites this paper
• Prognosis and Therapy of Ovarian Cancer: Part 2 – the Shifting Landscape of Medical Treatment in Ovarian Cancer

  2025cites this paper
• Clearer Horizons: The latest advances in clear cell ovarian cancer treatment.

  2025cites this paper
• Comparative efficacy and safety of low-dose versus high-dose bevacizumab in ovarian cancer: An indirect treatment comparison.

  2025cites this paper
• Failure of early interval debulking surgery after standard neoadjuvant chemotherapy: May bevacizumab add something? A large retrospective study.

  2025cites this paper
• Endocrine Maintenance Therapy in High-Grade Serous Ovarian Cancer: A Retrospective Off-Label Real-World Cohort Study

  2025cites this paper
• Targeting metabolic vulnerability by combining NAMPT inhibitors and disulfiram for treatment of recurrent ovarian cancer

  2025cites this paper
• Time to adjuvant chemotherapy and overall survival in advanced-stage ovarian cancer patients in England: a population-based retrospective cohort study

  2025cites this paper
• Comprehensive overview of antibody drug-related clinical studies in gynecology: insights from ClinicalTrials.gov

  2025cites this paper
• Role of tumor microenvironment in ovarian cancer metastasis and clinical advancements

  2025cites this paper
• A case report of small cell neuroendocrine carcinoma of the ovary and review of the literature

  2025cites this paper
• Proton beam therapy achieves excellent local control for recurrent epithelial ovarian cancer: a single-center retrospective study

  2025cites this paper
• Management of Advanced Ovarian Cancer: Current Clinical Practice and Future Perspectives

  2025influential citation
• Real-world ovarian cancer care and its survival impact on older adults: An observational study from the Australian National Gynae-Oncology Registry (NGOR).

  2025cites this paper
• Predictive Value of the KELIM Index for Progression-Free Survival in Ovarian Cancer Under Current Treatment Modalities

  2025cites this paper
• Worldwide Research Trends on the Immunotherapy-Based Treatment of Ovarian Cancers: A Bibliometric and Visual Analysis

  2025cites this paper
• Detecting vascular normalization in epithelial ovarian cancer

  2025cites this paper
• FUS-stabilized USP7 facilitates the bevacizumab resistance of ovarian cancer through deubiquitinating PTK2

  2025cites this paper
• Treatment tolerability associated with carboplatin dose based on actual versus adjusted body weight in patients with a body mass index ≥25 kg/m2 with advanced ovarian cancer.

  2025cites this paper
• The benefits and pitfalls of adding bevacizumab to neoadjuvant chemotherapy for advanced ovarian cancer: a meta-analysis.

  2025cites this paper
• Trends in Surgical Outcomes and Overall Survival Among Women Undergoing Debulking Surgery for Advanced Ovarian Cancer in the U.S: Analysis of the National Cancer Database

  2025cites this paper
• Epigenetic modulation of BARD1 to enhance anti-VEGF therapy

  2025cites this paper
• Anlotinib in cancer therapy: mechanisms of action, clinical applications, and future perspectives

  2025cites this paper
• Retrospective study of elderly patients with advanced ovarian cancer who did not undergo surgery

  2025cites this paper
• Efficacy and safety of pembrolizumab for the treatment of advanced or recurrent ovarian cancer: a meta-analysis based on single-arm studies

  2025cites this paper
• HERC2 as a Potential Biomarker for Prognosis and Response to Bevacizumab in Ovarian Cancer: A Bioinformatics Approach

  2025cites this paper
• The discovery of Bevacizumab. An historical reappraisal

  2025cites this paper
• Malignant ascites in ovarian cancer: New advances and translational opportunities

  2025cites this paper
• Management of early-stage ovarian cancer: open questions and debated issues.

  2025cites this paper
• The impact of cytoreductive surgery on outcomes in high tumor burden ovarian cancer after induction of PARP inhibitors

  2025cites this paper
• Predicting the Effect of Bevacizumab Therapy in Ovarian Cancer from H&E Whole Slide Images using Transformer

  2025cites this paper
• Maintenance bevacizumab following chemotherapy is associated with improved survival in patients with advanced and recurrent cervical cancer in a single-institution retrospective study

  2025cites this paper
• Integrating clinical-molecular data to predict PARP inhibitors efficacy in advanced ovarian cancer patients after interval cytoreductive surgery.

  2025cites this paper
• Primary Peritoneal Clear Cell Carcinoma Presenting with Nonspecific Gastrointestinal Symptoms in a 39-Year-Old Woman: A Case Report

  2025cites this paper
• Case report: Bevacizumab-induced cerebrovascular events: a case series report and literature review

  2025influential citation
• The effect of Bevacizumab treatment on the incidence of hypertension in patients with ovarian cancer: a systematic review and meta-analysis

  2025cites this paper
• X-Ray Irradiation Induces Oxidative Stress and Upregulates Intestinal Nrf2-Mrp2 Pathway, Leading to Decreased Intestinal Absorption of Valsartan

  2025cites this paper
• Bevacizumab beyond progression: Impact of subsequent bevacizumab re-treatment in patients with ovarian, fallopian tube, and peritoneal cancer after progression.

  2025cites this paper
• ctDNA as an Objective Marker for Postoperative Residual Disease in Primary Advanced High-Grade Serous Ovarian Cancer

  2025cites this paper
• The Oncology Team of The Karlovac General Hospital Was the First in Croatia To Perform Ovarian Cancer Surgery Using the Latest ICG Technology-Case Report

  2025cites this paper
• MDA-9/Syntenin as a therapeutic cancer metastasis target: current molecular and preclinical understanding

  2025cites this paper
• Predictive biomarkers for the efficacy of PARP inhibitors in ovarian cancer: an updated systematic review

  2025cites this paper
• Cost effectiveness of bevacizumab plus carboplatin paclitaxel versus carboplatin paclitaxel as front line for advanced ovarian cancer in Thailand

  2025influential citation
• Bevacizumab in frontline chemotherapy improved the survival outcome for advanced ovarian clear cell carcinoma: a multicenter retrospective analysis

  2025cites this paper
• The Impact of Carboplatin Dosing Design Using Adjusted Serum Creatinine on Carboplatin Plus Paclitaxel Therapy for Ovarian Cancer

  2025cites this paper
• Blocking Tumoral Angiogenesis VEGF/VEGFR Pathway: Bevacizumab—20 Years of Therapeutic Success and Controversy

  2025cites this paper
• Development and implementation of a novel metric score (SciMet) for scientific publications

  2025cites this paper
• Prognosis and Therapy of Ovarian Cancer, Part 1: Patient Selection and Surgical Management in Advanced Ovarian Cancer – What Tools Do We Have to Make the Right Decision?

  2025cites this paper
• Optimal bevacizumab treatment strategy in advanced ovarian cancer: A review.

  2025cites this paper
• Bevacizumab in recurrent epithelial ovarian cancer: real-world experience from a tertiary cancer hospital in India

  2025influential citation
• Efficacy of Maintenance Therapy With Adjuvant Chemotherapy of Three Steps in Patients Newly Diagnosed With Advanced Ovarian Cancer: A Phase II Randomised Clinical Trial

  2025cites this paper
• The antibody–drug conjugate targeting ROR1, NBE-002, is active in high-grade serous ovarian cancer preclinical models

  2025cites this paper
• Impact of clinical trial participation on the survival of patients with newly diagnosed advanced ovarian cancer

  2025cites this paper
• Ovarian cancer targeted therapy: current landscape and future challenges

  2025cites this paper
• The BEV1L study: Do real‐world outcomes associated with the addition of bevacizumab to first‐line chemotherapy in patients with ovarian cancer reinforce clinical trial findings?

  2025cites this paper
• How to differentiate primary mucinous ovarian tumors from ovarian metastases originating from primary appendiceal mucinous neoplasms: a review

  2025cites this paper
• Intraperitoneal Intraoperative Chemotherapy in Advanced Ovarian Cancer: Rethinking the Future Beyond Complete Macroscopic Resection

  2025cites this paper
• Management and Clinical Outcomes of Patients with Advanced Ovarian Cancer in Routine Clinical Practice in Spain: The OVOC Study

  2025cites this paper
• Characteristics and Outcomes of Children and Adolescents With Epithelial Ovarian Neoplasms From a Tertiary Cancer Centre in Western India: A Retrospective Study

  2025cites this paper
• Quantitative and qualitative metrics of tumor stroma in predicting ovarian cancer outcomes and expansion of its study with AI-based tools

  2025cites this paper
• Tumor Cells Enriched for Interferon and Inflammatory Programs Pre-Exist in High Grade Serous Ovarian Cancer and are Proportionately Significantly Increased Post Chemotherapy

  2025cites this paper
• A systematic review of phase I trials in patients with ovarian cancer.

  2025cites this paper
• Neutrophil infiltration in peritoneal metastasis affects prognosis in patients with ovarian cancer

  2025cites this paper
• Association between increased proteinuria induced by Bevacizumab, Ramucirumab, and Aflibercept and the risk of renal impairment and failure: a systematic review and meta-analysis

  2025cites this paper
• Participants’ perspectives of the advanced ovarian cancer biomarker study VALTIVE1: a qualitative study

  2025cites this paper
• Predictive and Prognostic Factors in Epithelial Ovarian Cancer: A Review

  2025cites this paper